News

GSK wins first FDA lung-cancer approval with Jideytro (zidesamtinib) in ROS1+ NSCLC

On 22 July 2026 the US Food and Drug Administration approved GSK's Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received a ROS1 tyrosine kinase inhibitor. It is GSK's first approved lung-cancer medicine, and the first regulatory payoff from its ~$10.6bn acquisition of Nuvalent.

Zidesamtinib is a selective, CNS-penetrant ROS1 inhibitor designed to overcome resistance mutations (including G2032R) and control brain metastases while sparing TRK-family kinases to reduce neurological toxicity. Approval was based on the Phase 1/2 ARROS-1 study: in 117 ROS1 TKI-pretreated patients the objective response rate was 44% (95% CI, 34-53%), with 78% of responders still in response at 12 months and 62% at 18 months. Subgroup efficacy included a 51% ORR after a single prior ROS1 TKI, 54% in G2032R-mutant disease, and a 48% intracranial ORR (20% complete intracranial responses).

The approval marks GSK's entry into the approved ROS1+ NSCLC market and validates its asset-acquisition strategy focused on differentiated, resistance-covering oncology targets.

More top stories